ZURICH (Reuters) – Lonza has signed a partnership agreement with Anthos Therapeutics, the Swiss company said on Thursday, to develop and manufacture an antibody treatment for blood clots.
Anthos, a biotech created by Blackstone Life Sciences and Novartis, will get access to Lonza’s drug substance, drug product and labeling/packaging services to speed the launch of Abelacimab, a treatment for patients at risk of thrombosis.
(Reporting by John Revill; editing by Thomas Seythal)
